RVMDRevolution Medicines, Inc.vs its industry peers
A metric-by-metric comparison of Revolution Medicines, Inc. against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVMD본 종목 | $43.9B#8 | — | 16.9x#8 | — | — | -88.5%#15 | — | -43.4%#13 | — | — | 343.5%#1 | — |
| VRTX | $130.4B#4 | 30.0x#6 | 6.4x#4 | 10.9x#8 | 8.9%#9 | 838.1%#3 | 34.8%#3 | 19.5%#7 | 25.0%#5 | — | — | — |
| AMGN | $203.1B#2 | 23.3x#5 | 17.4x#9 | 5.5x#3 | 10.0%#8 | 88.5%#7 | 24.7%#8 | 66.0%#2 | 15.1%#7 | — | — | 2.5%#1 |
| GILD | $181.4B#3 | — | 15.3x#7 | 6.2x#4 | 2.4%#10 | 1672.9%#2 | 34.0%#4 | 71.9%#1 | 26.7%#4 | — | 32.9%#5 | 2.2%#2 |
| REGN | — | 19.1x#3 | — | — | 1.0%#12 | 2.1%#11 | 24.9%#7 | 14.2%#8 | 9.4%#9 | — | 35.0%#4 | — |
| ARGX | $60.6B#5 | — | — | 1705.6x#13 | 254.4%#1 | 55.1%#8 | 2965.7%#1 | — | — | — | 29.4%#6 | — |
| ALNY | $31.9B#11 | 41.5x#8 | 23.5x#10 | 8.6x#7 | 65.2%#3 | 212.8%#4 | 13.5%#10 | 23.2%#4 | 150.5%#1 | — | -48.3%#9 | — |
| NTRA | $50.6B#7 | — | 27.8x#11 | 21.9x#9 | 35.9%#5 | -9.3%#12 | -13.4%#12 | -11.4%#11 | -18.0%#10 | — | 103.6%#2 | — |
| BIIB | $31.9B#10 | 23.2x#4 | 2.2x#1 | 3.2x#1 | 2.2%#11 | -20.8%#13 | 28.7%#6 | 8.7%#9 | 13.0%#8 | 4#3 | — | — |
| ILMN | $33.6B#9 | 41.5x#7 | 11.8x#6 | 7.7x#6 | -0.7%#13 | 169.5%#5 | 18.6%#9 | 30.0%#3 | 22.0%#6 | 7#1 | — | — |
| MRNA | $57.4B#6 | — | 8.5x#5 | 29.5x#10 | -39.9%#14 | 20.8%#9 | -158.1%#13 | -41.7%#12 | -54.6%#11 | — | — | — |
| INSM | $26.2B#12 | — | 34.6x#12 | 43.2x#11 | 66.7%#2 | -39.7%#14 | -205.6%#14 | -168.6%#14 | -163.0%#12 | 3#4 | — | — |
| ONC | $511.7B#1 | 805.0x#9 | 98.9x#13 | 95.8x#12 | 40.2%#4 | 144.5%#6 | 8.4%#11 | 5.5%#10 | 29.9%#3 | 6#2 | 4.2%#8 | — |
| INCY | $24.3B#13 | 17.2x#1 | 4.3x#3 | 4.7x#2 | 21.2%#6 | 3846.9%#1 | 29.5%#5 | 22.9%#5 | 49.0%#2 | — | 46.4%#3 | — |
| UTHR | $21.5B#14 | 17.9x#2 | 3.4x#2 | 6.7x#5 | 10.6%#7 | 11.7%#10 | 46.9%#2 | 20.9%#6 | — | — | 24.1%#7 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice